MHRA appoints two directors
This article was originally published in Scrip
TheMHRA, the UK medicines regulator, has named two new non-executive directors. Professor Barrington Furr retired from AstraZeneca in 2005 after more than 33 years with the company and its earlier incarnations. He lists consulting work for venture capital and biotechnology companies among his potential conflicts of interest, as well as work for Almirall and his role as a trustee of the Breast Cancer Campaign. Professor Vincent Lawton held senior positions at Merck Sharp and Dohme in Europe and North America in his 26 years with the company, and he continues to own stock and stock options. He is a trustee of the Association of the British Pharmaceutical Industry.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.